Pharma supply shortages drive calls for more integrated supply chains
Drug maker Pfizer sounded the alarm on 11 June that it would be running out ...
STAT reports:
A panel of outside experts on Thursday recommended the Food and Drug Administration issue an emergency use authorization to the Covid-19 vaccine being developed by Pfizer and BioNTech, a vaccine that appeared to be highly efficacious in a Phase 3 clinical trial.
The vote came after a long day in which members of the Vaccines and Related Biological Products Advisory Committee, or VRBPAC, discussed a wide range of issues related to the vaccine, including concerns about vaccinating people with severe allergies as well as issues regarding vaccination during pregnancy or lactation.
Although the FDA does not have to follow the panel’s recommendation, it is widely expected to do so.
The rollout of Covid-19 vaccine could then begin in the United States in a matter of days.
STAT’s coverage of the meeting is below, with updates and analysis posted in reverse chronological order.
To read all the updates, please click here.
Comment on this article